Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

ANRO

Alto Neuroscience Inc.

May 17 • 04:00PM ET

12.47

Dollar change -0.35
Percentage change -2.73	%

Healthcare • Biotechnology • USA • NYSE

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF SCHA SCHB IBRN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	17.15%	Shs Outstand	26.88M	Perf Week	-7.56%
Market Cap	335.19M	Forward P/E	-	EPS next Y	-3.11	Insider Trans	15.77%	Shs Float	22.12M	Perf Month	-7.63%
Income	-	PEG	-	EPS next Q	-0.66	Inst Own	60.20%	Short Float	11.25%	Perf Quarter	-21.37%
Sales	-	P/S	-	EPS this Y	71.03%	Inst Trans	-	Short Ratio	14.28	Perf Half Y	-
Book/sh	7.18	P/B	1.74	EPS next Y	-10.42%	ROA	-	Short Interest	2.49M	Perf Year	-
Cash/sh	7.66	P/C	1.63	EPS next 5Y	-	ROE	-	52W Range	12.40 - 24.00	Perf YTD	-39.76%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-48.04%	Beta	-
Dividend TTM	-	Quick Ratio	26.02	Sales past 5Y	-50.00%	Gross Margin	-	52W Low	0.56%	ATR (14)	1.09
Dividend Ex-Date	-	Current Ratio	26.02	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	38.31	Volatility	8.22% 7.47%
Employees	63	Debt/Eq	0.05	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.17	Target Price	35.55
Option/Short	No / Yes	LT Debt/Eq	0.05	EPS Q/Q	-	Payout	-	Rel Volume	0.51	Prev Close	12.82
Sales Surprise	-	EPS Surprise	-64.50%	Sales Q/Q	-	Earnings	May 14 AMC	Avg Volume	174.28K	Price	12.47
SMA20	-12.48%	SMA50	-14.12%	SMA200	-16.70%	Trades		Volume	89,015	Change	-2.73%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-27-24	Initiated	William Blair	Outperform
Feb-27-24	Initiated	TD Cowen	Outperform
Feb-27-24	Initiated	Stifel	Buy	$32
Feb-27-24	Initiated	Robert W. Baird	Outperform	$32
Feb-27-24	Initiated	Jefferies	Buy	$33

May-14-24 10:54PM	ANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024 (InvestorPlace)
04:03PM	Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
May-09-24 08:05AM	Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences (Business Wire) +5.19%
Apr-23-24 08:05AM	Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia (Business Wire)
Apr-10-24 03:30PM	Insiders are Piling into These 10 Healthcare Stocks in 2024 (Insider Monkey)
09:37AM	Loading…
Apr-09-24 09:37AM	Alto Neuroscience (ANRO): Strong Industry, Solid Earnings Estimate Revisions (Zacks)
Apr-03-24 08:05AM	Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder (Business Wire)
Mar-21-24 04:05PM	Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights (Business Wire)
Mar-11-24 08:05AM	Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors (Business Wire) +5.74%
Mar-07-24 08:00AM	Alto Neuroscience to Participate in Upcoming Investor Conferences (Business Wire)
Feb-27-24 08:00AM	Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference (Business Wire) -6.21%
Feb-06-24 04:05PM	Alto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (Business Wire) -11.06%
Feb-01-24 08:57PM	Alto Neuroscience Announces Pricing of Upsized Initial Public Offering (Business Wire)

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Los Altos, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Smith Nicholas Conrad	CHIEF FINANCIAL OFFICER	Mar 28 '24	Buy	16.36	6,150	100,628	26,866	Apr 01 04:15 PM
Alpha Wave Global, LP	10% Owner	Feb 06 '24	Buy	16.00	600,000	9,600,000	3,707,757	Feb 08 04:32 PM
Savitz Adam	CHIEF MEDICAL OFFICER	Feb 06 '24	Buy	16.00	17,000	272,000	24,851	Feb 07 04:38 PM
Etkin Amit	PRESIDENT AND CEO	Feb 06 '24	Buy	16.00	3,125	50,000	1,205,465	Feb 07 04:36 PM
Smith Nicholas Conrad	CHIEF FINANCIAL OFFICER	Feb 06 '24	Buy	16.00	1,563	25,008	1,563	Feb 07 04:40 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANRO

Alto Neuroscience Inc.

Upgrade your FINVIZ experience